Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...

Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...

We may earn commission from links on this page, but we only recommend products we love. Promise. Listen, I’ll be the first person to tell you that homemade face masks can be a little questionable.

Minecraft remains one of the best games of all time over a decade on from its release, but spending such a long time in one game could lead to you running out of ideas. We've been there: you've ...

Independent re/insurance broker BMS has appointed five executives to its newly created accident and health (A&H) division. The London-based team will provide A&H solutions without territorial or ...

Today, a brief rundown of news from Bristol Myers Squibb and Cytokinetics as well as updates from Disc Medicine and Teva Pharmaceutical that you may have missed.

I Feel Love’s innovative electronic rhythm section set the stage for pretty much everything that followed, and here’s how you can recreate its bewitching energy in your DAW ...